Brief: Neovacs And Centurion Pharma Continue Their Collaboration In Lupus

Neovacs SA

11/12/2018 06:47

Dec 11 (Reuters) - NEOVACS SA  ALNEV.PA :
    * NEOVACS AND CENTURION PHARMA CONTINUE THEIR COLLABORATION
IN
LUPUS BASED ON THE RESULTS OF THE PHASE IIB TRIAL WITH IFNALPHA
KINOID
    * STATUS OF ODD (ORPHAN DRUG DESIGNATION) IS ACTUALLY BEING
PREPARED FOR FILING IN SOUTH KOREA
    * ON A GLOBAL BASIS NEOVACS IS ACTUALLY PREPARING PROTOCOL
OF
PHASE III TRIAL AND WORKING ON STRATEGIES FOR REGISTRATION OF
IFNALPHA KINOID
    * AGREEMENT WITH CENTURION PHARMA HAS FORESEEN A GLOBAL
PAYMENT OF
6 MIO EUR TO NEOVACS
    * A FIRST PAYMENT HAS BEEN MADE IN 2017
    * FURTHER PAYMENTS ARE FORESEEN AND NEOVACS WILL ALSO
RECEIVE
ROYALTIES BASED ON NET SALES OF IFNALPHA KINOID IN TURKEY

Source text for Eikon:  ID:nGNE1RQlv0 
Further company coverage:  ALNEV.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com;))